Study finds Pfizer’s antiviral has little or zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week
August 25, 2022 at 10:33 AM EDT
Pfizer's COVID antiviral Paxlovid appears to have little or no benefit for younger adults, although it still reduces the risk of hospitalization or death in seniors, according to a new Israeli study.
